<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594115/" ref="ordinalpos=1700&amp;ncbi_uid=5863146&amp;link_uid=PMC3594115" image-link="/pmc/articles/PMC3594115/figure/F1/" class="imagepopup">Figure 1. <span class="highlight" style="background-color:">Pathway</span>-specific impairment of insulin <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> and endothelial dysfunction.  From: Role of Insulin Resistance in Endothelial Dysfunction. </a></div><br /><div class="p4l_captionBody">PI 3-kinase branch of insulin signaling regulates NO production and vasodilation in vascular endothelium. MAP-kinase branch of insulin signaling controls secretion of endothelin-1 (ET-1) and adhesion molecule expression in vascular endothelium. Glucotoxicity, lipotoxicity, and various cytokines activate signaling molecules that inhibit PI3K/Akt signaling. eNOS, endothelial nitric oxide synthase; IRS, insulin receptor substrate; MEK, MAPK kinase; PDK, phosphoinositide-dependent protein kinase; PKC, protein kinase C; IRS, insulin receptor substrate; ERK, extracellular signal-regulated kinase; JNK, C-Jun N-terminal kinase; p70S6K, p70 ribosomal S6 kinase; AP-1, activator protein-1; NO, nitric oxide; and ET-1, endothelin-1.</div></div>